Alpha Cognition宣布首位患者入组评估Zunveyl®用于轻中度阿尔茨海默病的Resolve第四期研究

美股速递
Jun 16

Alpha Cognition Inc.宣布,其Resolve第四期研究已迎来首位患者入组。这项研究旨在评估Zunveyl®在轻至中度阿尔茨海默病患者中的疗效与安全性。该里程碑标志着公司在该药物临床开发进程中的关键一步,为后续数据收集与分析奠定了基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10